Clinical Trials
Clinical Trials can be another treatment source as veterinarians discover new ways to diagnose cancer faster and improve the treatment outcomes. These veterinary clinical trials could be promising new treatments, drugs or procedures. Often the treatment costs in a clinical trial are covered by the clinical trial sponsor. Review this page below for potential clinical trials in your area as they relate to TCC. The clinical trial link will provide you more detailed information on the specific trial. Please reach out to the contact to obtain additional information.
Study Name
Information
New Clinical Trial for Dogs with Bladder Cancer in 2022 to determine how two drugs commonly used for TCC are stimulating anti-tumor immune responses, and how the sequence by which the drugs are given could improve treatment outcomes.
Location: Purdue University, Lafayette, Indiana
Recruitment starts January 2022
Primary Investigator:
Dr. Debbie Knapp
Primary Study Contact:
If you and your veterinarian would like for your dog to be evaluated for the trial, please ask your regular veterinarian to call the Purdue University Veterinary Hospital Oncology Service at (765)-494-1107 to refer the dog for an appointment.
EGFR/HER2 Vaccine (Yale Vaccine) developed by Dr. Mark Mamula at Yale for dogs has potential to inhibit EGFR signalling, boost antibodies and inhibit tumor growth. Consists of two shots, 3 weeks apart. Can be given along with chemotherapy or radiation treatments. Minimal side effects. Published study
EGFR protein is overexpressed in canine Transitional Cell Carcinoma. Preliminary data studying Osteosarcoma and Hemangiosarcoma is encouraging.
Locations:
Integrative Veterinary Oncology, Phoenix, AZ
Pacific and Santa Cruz Veterinary Specialists, Santa Cruz, CA
MedVet Chicago, Chicago, IL
MedVet Cincinnati, Fairfax, OH
MedVet Cleveland, Cleveland, OH
MedVet Pittsburgh, Pittsburgh, PA
MedVet Salt Lake City, Salt Lake City, UT
MedVet Northern Virginia, Madassas, VA
Bridge Animal Referral Center, Edmonds, WA
Washington State University, Veterinary Teaching Hospital, Pullman, WA
Investigator: Dr Mark Mamula 203-737-2840; mark.mamula@yale.edu
Phase I Clinical Trial of NCGC00413972 (NIH 972) in Dogs with Spontaneously Occurring Sarcomas
Safety of B7H3 CAR T cells in Dogs with Spontaneous Cancer
Location: Flint Animal Cancer Center, Colorado State University, Fort Collins, CO
Primary Study Contact: CSU Oncology Clinical Trials csuoncologytrials@colostate.edu 1-970-297-4001
Location: University of Illinois, College of Veterinary Medicine, Urbana, IL
Primary Study Contact: Clinical Trials Coordinator, Rebecca Kamerer, Email: rmoss81@illinois.edu Phone:(217) 300-6453
Clinical trial evaluating the impact of oclacitinib maleate (Apoquel®) on T regulatory cells in dogs receiving standard-of-care, maximum-tolerated-dose carboplatin chemotherapy for the treatment of naturally-occurring cancer.
Location: Kansas State University, Manhattan, KS
Primary Study Contact: Kris Richardson, Clinical Trials Coordinator at the Veterinary Health Center, for more information about this study. Phone: (785)-532-3046, email: ClinicalTrials@vet.k-state.edu
Clinical trial evaluating the impact of oclacitinib maleate (Apoquel®) on T regulatory cells in dogs receiving standard-of-care, maximum-tolerated-dose doxorubicin chemotherapy for the treatment of naturally-occurring cancer
Location: Kansas State University, Manhattan, KS
Primary Study Contact: Kris Richardson, Clinical Trials Coordinator at the Veterinary Health Center, for more information about this study. Phone: (785)-532-3046, email: ClinicalTrials@vet.k-state.edu
Location: Kansas State University, Manhattan, KS
Primary Study Contact: Kris Richardson, Clinical Trials Coordinator at the Veterinary Health Center, for more information about this study. Phone: (785)-532-3046, email: ClinicalTrials@vet.k-state.edu
THERAPEUTIC TRIAL FOR DOGS WITH BLADDER CANCER - Nutritional Supplement added to current treatment
Dogs with Bladder Cancer - evaluating a probiotic to improve cancer care and/or outcomes; Probiome for Canine Bladder Cancer; This study is heavily subsidized allowing your dog to be treated with Vinblastine for very little cost to the pet owner.
Location: North Carolina State University, Raleigh, NC
Principal Investigator: Claire Wiley: UCClinicalTrials@ncsu.edu
Location: North Carolina State University, Raleigh, NC
Primary Study Contact: Ashley Fuhrer, Phone: 919-515-3634, email: cvmclinicalstudies@ncsu.edu
Location #2: University of Missouri, Veterinary Health Center, Colombia, MO
Primary Study Contact Email: cvmclinicaltrials@missouri.edu
Location #3: Ohio State University, Veterinary Medical Center, Columbus, OH
Primary Study Contact Email: CVM-ClinicalTrials@osu.edu
Watch this short video describing the trial
Experimental immunotherapy (IL-12) for the treatment of bladder cancer in dogs
Location: North Carolina State University, Raleigh, NC
Principal Investigator: Dr. Paul Hess, cvmclinicalstudies@ncsu.edu or 919-515-3634
Evaluating the Tolerability of a Novel PCNA Inhibitor in Dogs with Cancer
Locations:
Massachusetts Veterinary Referral Hospital, Woburn, MA
Peak Veterinary Referral Center, Williston, VT
WVRC – Waukesha, Waukesha, WI
Canine Transitional Cell Carcinoma Study - Novel surgical procedure
Location: Oregon State University, Carlson College of Veterinary Medicine, Corvallis, OR
Investigator: Dr. Milan Milovancev (milan.milovancev@oregonstate.edu; 541-737-3527) or Dr. Jana Gordon (jana.gordon@oregonstate.edu; 541-737-4808)
Location: UC Davis Veterinary Medical Teaching Hospital, Davis, CA
Recruitment open (no dates are listed but it is “active/recruiting” on their web site)
Primary Study Contact:
PRINCIPAL INVESTIGATOR - Dr. Bill Culp
Email: wculp@ucdavis.edu • (530) 752-1393
Location: UC Davis Veterinary Medical Teaching Hospital, Davis, CA
Recruitment open from Apr 22, 2019 (“active/recruiting” on their web site)
Primary Study Contact:
Dr. Jodi Westropp
Email: jlwestropp@ucdavis.edu
(530) 752-1393
Location: UC Davis Veterinary Medical Teaching Hospital, Davis, CA
Recruitment open from Aug 21, 2017 (“active/recruiting” on their web site)
Primary Study Contact:
Principal Investigator - Dr. Luke Wittenburg, Assistant Professor
Oncology Clinical Trials Coordinators
Email: oncologyclinicaltrials@ucdavis.edu
(530) 754-1954
Effects of Ladarixin on quality of life and tumor response in dogs receiving chemotherapy
Location: Tufts Clinical Trials Office, Cummings Veterinary Medical Center, North Grafton, MA
Recruitment open
Primary Study Contact:
Email: clinicaltrials@tufts.edu
508-887-4441
Cancer Immunotherapy: Phase 1 trial for a new canine immunotherapy drug
Location: University of Minnesota, College of Veterinary Medicine, St. Paul, MN
Recruitment open
Primary Study Contact:
Amber Winter, CVT
Email: alwinter@umn.edu
612-624-1352
Phase I clinical trial to evaluate the biological effective dose and tolerability of trametinib in dogs with cancer
Location: University of Wisconsin Veterinary Care, Madison, Wisconsin
Primary Study Contact:
Marilia Takada, DVM, MS, PhD at takada@wisc.edu
David Vail, DVM, DACVIM (Onc) at david.vail@wisc.edu
Amanda Brooks, CVT at simons5@wisc.edu for more information.
Note: This is one of the drugs used by Fidocure for treating TCC
Location: Any Location
Primary Study Contact:
Hannah Peterson at hpeterson4@wisc.edu or Dr. Lauren Trepanier at lauren.trepanier@wisc.edu.
Pilot study of resiniferatoxin administered into the bladder to manage lower urinary tract discomfort in dogs with bladder transitional cell carcinoma
Location: Animal Medical Center, New York, NY
Primary Study Contact:
Dr. Chick Weisse at 212-838-8816 or email chick.weisse@amcny.org.
Location: Animal Medical Center, New York, NY
Primary Study Contact:
Dr. Nicole Liebman at 212-329-8740 or email nicole.leibman@amcny.org
Clinical and Safety Evaluation of Multiple Intravenous Administrations of Immunocidin® in Cats and Dogs with Malignancies
Location: Veterinary Cancer Care, Santa Fe, New Mexico
info@vetcancercare.com
505-982-4492